लुमाटेपेरोन और नेफाज़ोडोन का इंटरैक्शन

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes.

Strong CYP3A4 inhibitors: Recommended dosage is 10.5 mg once daily.

Moderate CYP3A4 inhibitors: Recommended dosage is 21 mg once daily.

Moderate or Strong CYP3A4 Inhibitors* Prevention or Management Reduce the CAPLYTA dosage when used concomitantly with moderate or strong CYP3A4 inhibitors [see Dosage and Administration ( 2.2 ) ].

Clinical Impact Concomitant use of CAPLYTA with moderate or strong CYP3A4 inhibitors increases lumateperone exposure [see Clinical Pharmacology ( 12.3 ) ] , which may increase the risk of adverse reactions.

Some cases presented with features resembling neuroleptic malignant syndrome.